Our mission is your grandfather.father.husband.son.brother.partner.
Progenics is poised to become a preeminent oncology company focused on developing innovative drugs to improve the lives of prostate cancer patients and their families. Our pipeline includes therapeutic and diagnostic candidates in pre-clinical through late-stage development.
Molecular Insight was acquired by Progenics in early 2013. The synergies between Molecular Insight’s focus on radiopharmaceutical therapeutics and diagnostic imaging agents, and our PSMA ADC expertise enable us to pursue a unique, multi-faceted approach to targeting, tracking and treating cancer.
We plan to further our mission by acquiring and developing oncology assets – companies and/or product candidates – that expand and complement our capabilities in the prostate cancer space. Product candidates outside our core focus will continue to be out-licensed or partnered with motivated drug developers.